Volume 8, Issue 1 (1-2019)                   WJPS 2019, 8(1): 116-119 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rouientan A, Alizadeh Otaghvar H, Mahmoudvand H, Tizmaghz A. Rare Complication of Botox Injection: A Case Report. WJPS 2019; 8 (1) :116-119
URL: http://wjps.ir/article-1-413-en.html
Plastic and Reconstructive Surgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran , rouientan@gmail.com
Abstract:   (4726 Views)
Botulinum toxin (BTX) is also well-known as Botox is produced by a gram-positive anaerobic bacterium called Clostridium botulinum. Generally, clinical manifestations of BTX can be observed after consumption of contaminated food, from colonization of the infant gastrointestinal tract, as well as following the infection of the wound to this bacterium. There are seven types of this neurotoxin labeled as A, B, C (C1, C2), D, E, and F. Human botulinum is caused by types A, B, E and rarely F. The most common clinical symptoms of BTX in cosmetic goals are cervical dystonia, severe primary axillary hyperhidrosis, strabismus, neurogenic detrusor over-activity, chronic migraine, upper limb spasticity and blepharospasm. Botox has a wide range of therapeutic uses and occasionally patients receiving this treatment may experience botulism symptom including local and even distant and autonomic symptoms. Despite the efficacies of Botox in treatment of myriad neurologic and cosmetic conditions, it may carry some risk of sever adverse effects which may be the result of local or systemic spreading of the drug. Our patient was a 22 years old man who received Botox for axillary hyperhidrosis after two weeks, when most of generalized complications of botulinum toxin appeared. This case was introduced for being aware of dangerous complication of Botox. Pyridostigmine could relieve symptoms of the patient.
Full-Text [PDF 260 kb]   (2810 Downloads)    
Type of Study: case report | Subject: General
Received: 2018/04/27 | Accepted: 2019/03/13 | Published: 2019/03/13

1. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology 1999;53:1850-3. doi: 10.1212/wnl.53.8.1850 . PubMed PMID: 10563638. [DOI:10.1212/WNL.53.8.1850]
2. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999;96:3200-5. doi: 10.1073/pnas.96.6.3200. PubMed PMID: 10077661; PubMed Central PMCID: PMC15919.
3. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Südhof TC, Niemann H, Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160. Doi: 10.1038/365160a0. [DOI:10.1038/365160a0]
4. Wohlfarth K, Schwandt I, Wegner F, Jurgens T, Gelbrich G, Wagner A, Bogdahn U, Schulte-Mattler W. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 2008;255:1932-9. doi: 10.1007/s00415-008-0031-7. [DOI:10.1007/s00415-008-0031-7]
5. Frevert J. Content of botulinum neurotoxin in botox®/vistabel®, dysport®/azzalure®, and xeomin®/bocouture®. Drugs in R & D 2010;10:67-73.doi: 10.1007/bf03259776. [DOI:10.1007/BF03259776]
6. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl 1997;6:S129-45 doi: 10.1002/(sici)1097-4598(1997)6+<129::aid-mus9>3.0.co;2-b. https://doi.org/10.1002/(SICI)1097-4598(1997)6+<129::AID-MUS9>3.0.CO;2-B [DOI:10.1002/(SICI)1097-4598(1997)6+3.0.CO;2-B]
7. Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 2018;147:84-8. doi: 10.1016/j.toxicon.2017.09.003. [DOI:10.1016/j.toxicon.2017.09.003]
8. Wilkes J. AAN Updates Guidelines on the Uses of Botulinum Neurotoxin. Am Fam Physician 2017;95:198-9.
9. Dutta SR, Passi D, Singh M, Singh P, Sharma S, Sharma A. Botulinum toxin the poison that heals: A brief review. Natl J Maxillofac Surg 2016;7:10-6. doi: 10.4103/0975-5950.196133. [DOI:10.4103/0975-5950.196133]
10. Taillac PP, Kim J. CBRNE - Botulism. Medscape Reference. Updated June 6, 2006. Available from: http://emedicine.medscape.com/article/829125-overview
11. Edell TA, Sullivan CP, Jr., Osborn KM, Gambin JP, Brenman RD. Wound botulism associated with a positive tensilon test. West J Med 1983;139:218-9.
12. Denys EH, Norris FH, Jr. Amyotrophic lateral sclerosis. Impairment of neuromuscular transmission. Arch Neurol 1979;36:202-5. Doi: 10.1001/archneur.1979.00500400056008. [DOI:10.1001/archneur.1979.00500400056008]
13. Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, Pavlopoulos A, McWilliams LG, Schmidt JG, Martinez RA, Ashley DL. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis 2005;11:1578-83. doi: 10.3201/eid1110.041279. [DOI:10.3201/eid1110.041279]
14. Gutierrez AR, Bodensteiner J, Gutmann L. Electrodiagnosis of infantile botulism. J Child Neurol 1994;9:362-5. doi: 10.1177/088307389400900404. [DOI:10.1177/088307389400900404]
15. Maselli RA, Bakshi N. AAEM case report 16. Botulism. American Association of Electrodiagnostic Medicine. Muscle Nerve 2000;23:1137-44. https://doi.org/10.1002/1097-4598(200007)23:7<1137::AID-MUS21>3.0.CO;2-7 [DOI:10.1002/1097-4598(200007)23:73.0.CO;2-7]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | World Journal of Plastic Surgery

Designed & Developed by : Yektaweb